Mixed pathologies in pancreatic beta-cells from subjects with neurodegenerative diseases and their interaction with prion protein
Objective: We studied whether, as in the brain, pancreatic -cells of subjects with neurodegenerative diseases also present co-occurrence of other misfolded proteins. Furthermore, we also assessed…Naturalistic study of depression and Parkinson´s Disease in a third level of attention in Mexico City
Objective: Describe the sociodemographic and clinical variables of patients with Parkinson's disease (PD) diagnosed with major depressive disorder (MDD) in the outpatient clinic (OC) of…Neural activity in the subthalamic nucleus in association with reward/loss processing in patients with Parkinson’s disease
Objective: To elucidate the electrophysiological correlates of the reward and loss processing during incentive anticipation and feedback in the subthalamic nucleus (STN) of patients with…Site investigator perspectives on exclusionary determinations of SWEDDs (Scans Without Evidence of Dopaminergic Deficit) during screening in the SURE-PD3 study
Objective: To assess investigators’ level of agreement with centrally adjudicated SWEDDs based on dopamine transporter imaging (qualitatively defined) during screening of subjects whom investigators had…Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials
Objective: Evaluate the effects of ADS-5102 (amantadine) extended release capsules on motor complications and functional outcomes among patients experiencing both troublesome dyskinesia and OFF (disruptive…Clinical Implication of Stimulus Induced Dyskinesia in Pallidal Deep Brain Stimulation for Advanced Parkinson’s Disease
Objective: To investigate the influence of stimulus induced dyskinesia (SID) on the therapeutic outcome of globus pallidus internus (GPi) deep brain stimulation (DBS) for the…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Researches on the correlation between wearable device data and UPDRS scores in patients with Parkinson’s disease
Objective: To collect spatiotemporal parameter information of motor symptoms in patients with Parkinson's disease (PD) using wearable device, and analyze its correlation with the Unified…Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson’s disease patients
Objective: To evaluate the safety, pharmacokinetics (PK) and efficacy of single-dose apomorphine inhalation in PD patients. Background: Apomorphine is a dopamine agonist, approved for treating…Refining Knowledge on the Treatment of Pisa Syndrome with Botulinum Toxin
Objective: To analyze the efficacy of botulinum toxin (BoNT) in cases of pisa syndrome (PS) associated with Parkinson's disease (PD) targeting paraspinal muscles ipsilateral to…
- 1
- 2
- 3
- …
- 149
- Next Page »